Commemorating Completion of 1200 Transplants at AFBMTC/NIBMT
Feb 2022
Dear friends and colleagues,
On behalf of the Organizing Committee of ASH Live Review Pakistan, we welcome you to this historical event. This is the first American Society of Hematology (ASH) Licensed event in this part of the world. This scientific programme will offer a selection of studies describing latest advances in hematology and cutting-edge educational sessions with world experts. The program will provide a unique opportunity to share local data , real world experiences and challenges of developing countries. The event is organized by Armed Forces Bone Marrow Transplant Centre National Institute of Blood and Marrow Transplant (AFBMTC /NIBMT), located in Rawalpindi, Pakistan. Established in 2001, AFBMTC/NIBMT is the only dedicated transplant centre of the country with capability of performing more than 150 allogeneic transplants year. AFBMTC/NIBMT is also the only centre of Pakistan to have a cellular therapy programme and an in house mesenchymal stem cell culture facility since 2015. This website will also provide you a chance to virtually explore Pakistan, one of the Forbes preferred tourist destination in 2020 and the land of nature and adventure. We are delighted to welcome our friends and participants from all over the world to the ASH Live Review Pakistan: Selected Highlights from the 2020 ASH Annual Meeting. We hope that this event will increase knowledge, skill, networking with new friends and colleagues and, last but not the least, to enjoy the Pakistani culture.
Prof Dr Qamar Un Nisa Chaudhry
Professor of Clinical Haematology & BMT Physician
AFBMTC/NIBMT, Rawalpindi - PK
Khurram Tariq, MD FACP
Chair, Dept of Hematology and medical Oncology
Seby B. Jones Cancer Center
Hematologist and medical oncologist
Boone, NC USA
Prof Dr Parvez Ahmed
Professor, Director Bone Marrow Transplant
Quaid-e-Azam International Hospital,
Islamabad - PK
Dr Syed Kamran Mahmood
Consultant Medical Specialist & BMT Physician
AFBMTC/NIBMT, Rawalpindi - PK
Dr Raheel Iftikhar
Consultant Clinical Hematologist & BMT Physician
AFBMTC/NIBMT, Rawalpindi -
AFBMTC/NIBMT
Rawalpindi – Pakistan
Please wait while flipbook is loading. For more related info, FAQs and issues please refer to DearFlip WordPress Flipbook Plugin Help documentation.
EST: 0800-0930 | PST: 1700-1830 |
Session – I
Hematological Malignancies
Topic
Acute Myeloid Leukemia & MDS
Moderator
AFBMTC/NIBMT
Rawalpindi – PK
Speaker & Panelist
University of Illinois Hospital
Chicago – IL
West Penn Hospital
Pittsburgh – PA
Panelist
National Institute of Blood Diseases & BMT
Karachi – PK
CTCA Outpatient Care Center
Chicago, IL – USA
EST: 0930-1025 | PST: 1830-1925 |
Session – II
Benign Hematology
Topic
Coagulation and Thrombosis
Moderator
AFBMTC/NIBMT
Rawalpindi – PK
Speaker & Panelist
University of Texas MD Anderson Cancer Centre
Texas- USA
Panelist
King’s College Hospital – NHS Foundation Trust
London – UK
Kulsum International Hospital
Islamabad – PK
Hemophilia Patients Welfare Society
Rawalpindi – PK
The Aga Khan University Hospital
Karachi – PK
EST: 1025-1130 | PST: 1925-2030 |
Session – III
Hematological Malignancies
Topic
Acute Lymphoblastic Leukemia
Moderator
AFBMTC/NIBMT
Rawalpindi – PK
Speaker & Panelist
American Hospital
Dubai – UAE
Panelist
CTCA Outpatient Care Center
Chicago, IL – USA
The Aga Khan University
Karachi – PK
Quaid-e-Azam International
Islamabad – PK
EST: 0800-0900 | PST: 1700-1800 |
Session – IV
Hematological Malignancies
Topic
Lymphoma
Moderator
SKMCH & RC
Lahore – PK
Speaker & Panelist
City of Hope National Medical Center
Duarte, CA – USA
The Ohio State University
Columbus, OH – USA
Panelist
UT Southwestern Medical Center
Dallas, TX – USA
Chicago Ridge, IL
Rashid Nursing Home & Cancer Center
Rawalpindi – PK
EST: 0900-1030 | PST: 1800-1930 |
Session – V
Hematological Malignancies
Topic
Lymphoma & CAR-T
Moderator
Shifa International Hospital
Islamabad – PK
Speaker & Panelist
MD Anderson Cancer Center
Houston, TX – USA
Toni Stephenson lymphoma centre at city of hope, Duarte, CA USA
Panelist
The Ohio State University
Columbus – USA
SKMCH & RC
Lahore – PK
EST: 1030-1130 | PST: 1930-2030 |
Session – VI
Hematological Malignancies
Topic
Myeloproliferative Neoplasms
Moderator
AFBMTC/NIBMT
Rawalpindi – PK
Speaker & Panelist
Mayo Foundation for Medical Education & Research
Rochester, FL – USA
Panelist
City of Hope National Medical Center
Duarte, CA – USA
University of Illinois Hospital
Chicago – IL
The Aga Khan University Hospital
Karachi – PK
EST: 0800-0840 | PST: 1700-1740 |
Session – VII
Benign Hematology
Topic
Bone Marrow Failure Syndromes
Moderator
AFBMTC/NIBMT
Rawalpindi – PK
Speaker & Panelist
AFBMTC/NIBMT
Rawalpindi – PK
Panelist
Quaid-e-Azam International Hospital
Islamabad – PK
The Aga Khan University Hospital
Karachi – PK
KFSHRC · Oncology Center
Riyadh – KSA
EST: 0840-0940 | PST: 1740-1840 |
Session – VIII
Multiple Myeloma
Topic
Multiple Myeloma & Amyloidosis
Moderator
CMH
Bahawalpur
Speaker
Hollings Cancer Center – MUSC Health
Charleston, SC – USA
Panelist
UNC-CH School of Medicine
Chapel Hill, NC – USA
Hameed Latif Hospital
Lahore – PK
Ohio State University Wexner Medical Center Columbus Ohio, USA
The Johns Hopkins University School of Medicine
Baltimore, MD – USA
Shifa International Hospital
Islamabad – PK
EST: 0940-1030 | PST: 1840-1930 |
Session – IX
Benign Hematology
Topic
Hemoglobinopathies
Moderator
Gambat Institute of Medical Scienecies Gambat – PK
Speaker & Panelist
University of Illinois Hospital
Chicago, IL – USA
Panelist
St. Paul’s Hospital
Vancouver, Canada
Shifa International Hospital
Islamabad – PK
AFBMTC/NIBMT
Rawalpindi – PK
EST: 1030-1130 | PST: 1930-2030 |
Session – X
Transplantation & CAR-T Cell
Topic
Complications of HSCT
Moderator
The Aga Khan University Hospital
Speaker & Panelist
Mayo Foundation for Medical Education and Research
Rochester, Minnesota – USA
Panelist
UT Southwestern Medical Center
Dallas, TX – USA
AFBMTC/NIBMT
Rawalpindi – PK
The Aga Khan Univeristy Hospital
Karachi – PK
1. Abstract # 333. Efficacy and safety of Venetoclax in combination with Gilteritinib for R/R FLT3-mutated AML in the expansion cohort of a phase 1b. Daver et al.
2. Abstract # 693: Outcomes of TP53 mutant AML with Venetoclax and Decitabine. Kim et al.
1. Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Bas
eline Erythropoietin Levels
2. Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study
1. Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial
2. A Retrospective Cohort Study Evaluating the Safety and Efficacy of Peri-Partum Tranexamic Acid for Women with Inherited Bleeding Disorders
1. Superior Event-Free Survival with Blinatumomab Versus Chemotherapy in Children with High-Risk First Relapse of B-Cell Precursor Acute Lymphoblastic Leukemia: A Randomized, Controlled Phase 3 Trial
2. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study
Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension
1. Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study
2. Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)
1. Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
2. Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients
1. Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-
2 and/or BCL-6 Gene Rearrangements or Increase Copy Number 2.Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma
1. Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms
2. abstract 481 long term use of ropeginterferon alpha 2b in PV 5 year results from a randomized controlled study
1.A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia: (FluCAB-Prime)
2. Disease Progression and Outcomes in Patients with Telomere Biology Disorders
1. Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
2. Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial
3. Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
4. CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
1. Safety and efficacy of CTX001 in patients with transfusion-dependent beta-thalassemia and sickle cell disease: early results from the Climb THAL-111 and Climb SCD-121 studies of autologous CRISPR-CAS9-modified CD34+ hematopoietic stem and progenitor cells
1. Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213
2. REACH 3 trial: Ruxolitinib for cGVHD 3. Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study
If you have any questions about the event or the team of lecturers, please send us a message and we will reply shortly.
Conference Secretariat:
AFBMTC/NIBMT, CMH Medical Complex, Rawalpindi – Pakistan
Tel: +92 51 9270076 Ext 228, Cell & WhatsApp: +92 322 5181302, +92 310 2500292
Email: WBMT2022Pakistan@gmail.com